Please ensure Javascript is enabled for purposes of website accessibility

Why Legend Biotech Stock Is Sinking Today

By George Budwell – Sep 21, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A customs investigation is sending this Chinese biotech stock lower today.

What happened

Shares of the Chinese anti-cancer cell therapy specialist Legend Biotech (LEGN -0.62%) are poised for a rough session today. Ahead of the opening bell Monday morning, the biotech's stock fell by as much as 15.8% in response to the news that the Customs Anti-Smuggling Department of the People's Republic of China (PRC) inspected offices associated with both its parent majority shareholder, GenScript Biotech Corporation, and some of its own subsidiaries in the country.

Legend said this customs inspection appears to be related to suspected violations of import and export regulations under the laws of the PRC. As part of this investigation, the biotech's Chief Executive Officer, Fangliang Zhang, has reportedly been placed under residential surveillance by PRC law enforcement. In response, Legend has named its current Chief Financial Officer, Ying Huang, as interim CEO, effective immediately.

A man getting punched in the face.

Image source: Getty Images.

So what

While it's not altogether clear how this investigation will impact the biotech's all-important collaboration with Johnson & Johnson for the experimental multiple myeloma therapy cilta-cel (aka JNJ-4528), investors rarely like to see a company come under scrutiny by a governmental agency of any kind. And this rule of thumb arguably applies doubly so for Chinese companies due to the lack of transparency within the PRC in general. 

Now what

Legend's core investing thesis isn't sunk by any stretch of the imagination. But this customs investigation -- until it is resolved one way or another -- is almost certainly going to weigh on the biotech's shares. Bargain hunters, in turn, may want to watch this beaten-down biotech stock from the safety of the sidelines for now. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Legend Biotech Corporation Stock Quote
Legend Biotech Corporation
$40.11 (-0.62%) $0.25
Johnson & Johnson Stock Quote
Johnson & Johnson
$164.53 (-1.10%) $-1.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.